{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}],"title":"End of Treatment, CS change from BL, n=198, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"377"}]}],"title":"End of Treatment, NCS change from BL, n=198, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"End of Treatment, Not applicable, n=198, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"title":"24-week FU, CS change from BL, n=186, 369"},{"categories":[{"measurements":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"361"}]}],"title":"24-week FU, NCS change from BL, n=186, 369"}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"383"}],"units":"Participants"}],"description":"Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS or a NCS change from baseline in ECG status was reported, as determined by the Investigator based on a reasonable standard of clinical judgment. \"Not applicable\" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"End of Treatment (up to Week 52); and 24-week FU (up to Week 72)","title":"Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"participants"}